GlobeNewswire: Insmed, Inc. Contains the last 10 of 86 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:38:29ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/12/04/1661699/0/en/Insmed-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=26712Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)2018-12-04T13:30:00Z<![CDATA[BRIDGEWATER, N.J., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.]]>https://www.globenewswire.com/news-release/2018/11/08/1648003/0/en/Insmed-Announces-Changes-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=26712Insmed Announces Changes to its Board of Directors2018-11-08T13:30:00Z<![CDATA[—Seasoned Pharmaceutical Executive Elizabeth McKee Anderson Appointed as New Director—]]>https://www.globenewswire.com/news-release/2018/11/06/1646030/0/en/Insmed-to-Present-at-Three-November-Conferences.html?f=22&fvtc=4&fvtv=26712Insmed to Present at Three November Conferences2018-11-06T13:30:00Z<![CDATA[BRIDGEWATER, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following investor conferences:]]>https://www.globenewswire.com/news-release/2018/10/30/1638986/0/en/Insmed-Reports-Third-Quarter-2018-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=26712Insmed Reports Third Quarter 2018 Financial Results and Provides Business Update2018-10-30T11:30:00Z<![CDATA[—Quarter Highlighted by U.S. FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), Followed by Immediate Launch—]]>https://www.globenewswire.com/news-release/2018/10/23/1625417/0/en/Insmed-to-Host-Third-Quarter-2018-Financial-Results-Conference-Call-on-Tuesday-October-30-2018.html?f=22&fvtc=4&fvtv=26712Insmed to Host Third Quarter 2018 Financial Results Conference Call on Tuesday, October 30, 20182018-10-23T12:30:00Z<![CDATA[BRIDGEWATER, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its third quarter 2018 financial results on Tuesday, October 30, 2018.]]>https://www.globenewswire.com/news-release/2018/10/11/1619939/0/en/Insmed-Presents-New-Data-at-IDWeek-2018-and-CHEST-Annual-Meeting-Enhancing-the-Understanding-of-MAC-Lung-Disease-and-Treatment-with-ARIKAYCE-amikacin-liposome-inhalation-suspension.html?f=22&fvtc=4&fvtv=26712Insmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting Enhancing the Understanding of MAC Lung Disease and Treatment with ARIKAYCE® (amikacin liposome inhalation suspension)2018-10-11T12:30:00Z<![CDATA[BRIDGEWATER, N.J., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the Company presented data at IDWeek 2018 and at the CHEST Annual Meeting that provide additional insight into Mycobacterium avium complex (MAC) lung disease, a chronic and debilitating condition that can significantly increase patient morbidity and mortality. The Company also presented additional data from clinical trials of ARIKAYCE® (amikacin liposome inhalation suspension), the first and only therapy approved in the U.S. for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. ARIKAYCE received accelerated approval from the U.S. Food and Drug Administration (FDA) on September 28, 2018.]]>https://www.globenewswire.com/news-release/2018/10/04/1613220/0/en/Insmed-Extends-Patent-Protection-in-Japan-to-2033.html?f=22&fvtc=4&fvtv=26712Insmed Extends Patent Protection in Japan to 20332018-10-04T20:30:00Z<![CDATA[New Patent Adds 7 ½ Years of Market Exclusivity in Japan New Patent Adds 7 ½ Years of Market Exclusivity in Japan]]>https://www.globenewswire.com/news-release/2018/10/01/1587713/0/en/Insmed-to-Present-at-Two-October-Conferences.html?f=22&fvtc=4&fvtv=26712Insmed to Present at Two October Conferences2018-10-01T12:00:00Z<![CDATA[BRIDGEWATER, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that management will participate in the following investor conferences:]]>https://www.globenewswire.com/news-release/2018/09/28/1587346/0/en/Insmed-Announces-FDA-Approval-of-ARIKAYCE-amikacin-liposome-inhalation-suspension-the-First-and-Only-Therapy-Specifically-Indicated-for-the-Treatment-of-Mycobacterium-Avium-Complex.html?f=22&fvtc=4&fvtv=26712Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options2018-09-28T21:58:33Z<![CDATA[—Commercial availability expected in early Q4 2018—]]>https://www.globenewswire.com/news-release/2018/09/17/1571659/0/en/Pivotal-Phase-3-Data-from-CONVERT-Study-of-ALIS-in-Patients-with-Treatment-Refractory-NTM-Lung-Disease-Caused-by-MAC-Published-in-American-Journal-of-Respiratory-and-Critical-Care-.html?f=22&fvtc=4&fvtv=26712Pivotal Phase 3 Data from CONVERT Study of ALIS in Patients with Treatment-Refractory NTM Lung Disease Caused by MAC Published in American Journal of Respiratory and Critical Care Medicine2018-09-17T12:00:00Z<![CDATA[--As previously reported, study met primary endpoint of culture conversion (p<0.0001)----ALIS under FDA Priority Review with PDUFA action date of September 28, 2018--]]>